Matthew Pink

Company: Biodesix

Job title: VP, Business Development

Seminars:

Leveraging Multi-Omic Testing to Advance RAS-Targeted Cancer Therapies 10:15 am

Innovations in RAS Mutation Detection and Personalized Treatment: ddPCR™ testing enhances the detection of RAS mutations, facilitating earlier diagnosis, personalized therapy development, and longitudinal monitoring of disease recurrence in RAS-mutant cancers. Integrating Proteomics for Comprehensive RAS Targeting: Proteomic testing identifies a patients' immune response to RAS mutant positive cancers, enabling the identification of aggressive cancer…Read more

day: Day Two